VIP is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing. VIP is not fda-approved. orphan drug designation for pulmonary hypertension. fda announced plans to remove from compounding lists.
What Does the Research Say About VIP?
Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
VIP (Vasoactive Intestinal Peptide) is a Neuropeptide, vasodilator, anti-inflammatory. Research interest has focused on its potential effects on vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
What Is the Evidence for VIP's Mechanism?
Activates VPAC1 and VPAC2 class B G protein-coupled receptors, initiating adenylyl cyclase-cAMP cascade and CREB phosphorylation. Drives smooth muscle relaxation via calcium channel modulation, vasodilation through nitric oxide and prostacyclin production, neuroprotection via anti-inflammatory IL-10 induction, and enhanced insulin secretion via VPAC2 signaling.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for VIP?
Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, VIP has shown preliminary results.
What Does the Safety Research Show?
Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies.
VIP is not fda-approved. orphan drug designation for pulmonary hypertension. fda announced plans to remove from compounding lists.
What Makes VIP Unique in Research?
The only peptide addressing vasodilation, bronchoprotection, AND neuroprotection through a single receptor family — but its 2-minute half-life makes practical delivery the primary challenge.
This differentiator is important because it means VIP fills a role that other compounds in its class may not fully replicate.
Bottom Line on VIP Research
The evidence base for VIP is growing. Key research areas include vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
Stay current with PubMed searches for VIP for the latest publications.
Complete Guide
VIP : Benefits, Dosage, Side Effects & Research
Related Reading
- VIP Dosage Guide
- VIP Benefits
- VIP Side Effects
- VIP Stacking Guide
- VIP Cycle Guide
- Dihexa Complete Guide
Calculate Your VIP Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for VIP.
Open Calculator →Research-Grade Sourcing
If you're going to research VIP, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is VIP?
VIP (Vasoactive Intestinal Peptide) is a Neuropeptide, vasodilator, anti-inflammatory. Endogenous 28-amino acid neuropeptide produced in gut, pancreas, brain, and neuroendocrine tissues. It is researched for vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
What is the recommended VIP dosage?
Common dosages: 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) via intranasal spray or inhalation. Cycle length: ongoing continuous therapy. Half-life: 2 minutes (extremely short). Use our peptide calculator for exact reconstitution math.
What are the side effects of VIP?
Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies.
Is VIP safe?
VIP has shown a favorable safety profile in research. Not FDA-approved. Orphan drug designation for pulmonary hypertension. FDA announced plans to remove from compounding lists. All research should follow appropriate safety protocols.